Intensity Therapeutics (Intensity Therapeutics) EBIT per Share : $-1.73 (TTM As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Intensity Therapeutics EBIT per Share?

Intensity Therapeutics's EBIT per Share for the three months ended in Mar. 2024 was $-0.34. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.73.

During the past 3 years, the average EBIT per Share Growth Rate was -41.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Intensity Therapeutics's EBIT per Share or its related term are showing as below:

INTS' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -41.5 Med: -31.4 Max: -21.3
Current: -41.5

During the past 5 years, the highest 3-Year average EBIT per Share Growth Rate of Intensity Therapeutics was -21.30% per year. The lowest was -41.50% per year. And the median was -31.40% per year.

INTS's 3-Year EBIT Growth Rate is ranked worse than
87% of 1300 companies
in the Biotechnology industry
Industry Median: 3.4 vs INTS: -41.50

Intensity Therapeutics's EBIT for the three months ended in Mar. 2024 was $-4.60 Mil.

Intensity Therapeutics EBIT per Share Historical Data

The historical data trend for Intensity Therapeutics's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intensity Therapeutics EBIT per Share Chart

Intensity Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

-0.32

-0.34

-0.60

-0.57

-1.19

Intensity Therapeutics Quarterly Data
	Dec19	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT per Share	Get a 7-Day Free Trial											-0.10	-0.99	-0.17	-0.23	-0.34

Intensity Therapeutics EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Intensity Therapeutics's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-10.233	/	8.616
=	-1.19

Intensity Therapeutics's EBIT per Share for the quarter that ended in Mar. 2024 is calculated as

	EBIT per Share		(Q: Mar. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-4.603	/	13.709
=	-0.34

EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.73

Intensity Therapeutics (NAS:INTS) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Intensity Therapeutics EBIT per Share Related Terms

Thank you for viewing the detailed overview of Intensity Therapeutics's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Intensity Therapeutics (Intensity Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Intensity Therapeutics Inc (NAS:INTS) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

61 Wilton Road, 3rd Floor, Westport, CT, USA, 06880

Website

https://www.intensitytherapeutics.com

Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors.

Executives

Emer Leahy	director	1111 LINCOLN ROAD, SUITE 500, MIAMI BEACH FL 33139
Daniel Donovan	director	712 VISTA BLVD #305, WACONIA MN 55387
James M Ahlers	officer: Executive VP of CF	2000 POWELL STREET, SUITE 1640, EMERYVILLE CA 94608
Lewis H Bender	director, 10 percent owner, officer: President and CEO	765 OLD SAW MILL RIVER RD, TARRYTOWN NY 10591
Mark A Goldberg	director	PERCEPTIVE INFORMATICS INC, 200 WEST STREET, WALTHAM MA 02451
John M Wesolowski	officer: Interim CFO	61 WILTON ROAD, 3RD FLOOR, WESTPORT CT 06880